Point72 Asia (Singapore) Pte. Ltd. Astria Therapeutics, Inc. Call Options Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $381 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATXS
# of Institutions
120Shares Held
51.1MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$25.7 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$20.2 Million0.57% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$16.6 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$15.1 Million4.93% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$14.1 Million6.47% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $60.1M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...